BioSpace News Archive

Gemina Laboratories Ltd. is delighted to announce the appointment of Dr. Bola Grace to the Board of Directors.

Apnimed, Inc. today announced that company management will participate in 1x1 investor meetings at the SVB Securities Global Biopharma Conference taking place virtually January 31- February 2, 2023.

AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC) announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

Advarra, the market leader in regulatory review solutions, clinical research technology for sites and sponsors, and research quality and compliance consulting services, announced today that Scott Hoffman has joined the company as Chief Commercial Officer.

Leading life science platforms join to accelerate customers’ roadmap toward Data+Intelligence

Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028 Report Highlights:

Parent Project Muscular Dystrophy (PPMD) today announced a $500,000 programmatic investment in Myosana Therapeutics, Inc. (Myosana) to support the company’s continuing development and translation of a non-viral gene therapy delivery platform aiming to slow skeletal muscle degeneration and heart failure in Duchenne.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA).